You must be logged in and own this session in order to
1/13/21 11:56 am
Nice study sir.
Congrats on this effort by your research team.
With this qualities from Anti‑SARS‑CoV‑2 Multivalent DARP molecules reported h in your published work on this candidate, which included high antiviral effect, high yield, long systemic half-life, it is an impressive work undeed.
As your team stated, it could have potential for single-dose use in clinical usage.
This potential will then be your focus to validate it. If it comes out fine, which we hope, then we could have another clinical tool against Covid19 in our hands.
1/13/21 12:00 pm
Reference from your team's pre-print version:
Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates
Marcel Walser, Sylvia Rothenberger, Daniel L. Hurdiss, et al..
COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv.
I commend this team.